Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka.
J Interferon Cytokine Res. 2011 Aug;31(8):589-99. doi: 10.1089/jir.2010.0128. Epub 2011 Feb 25.
The therapeutic efficacy of interferon (IFN) for the hepatitis C is closely related with mutations in interferon sensitivity determining region or V3 domain of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A). However, the relationship between alanine aminotransferase (ALT) normalization and the NS5A variability remains unclear. To clarify these features of NS5A, we examined the genetic variability of the patients' NS5A from 33 HCV genotype 1b-infected patients: 11 sustained virological response (SVR), 11 end-of-treatment response (ETR) with normal ALT (<40 IU/L), and 11 non-response (NR) with abnormal ALT (>40 IU/L) after IFN treatment for >24 weeks. The amino acid in position 2378 (followed by HCV-J prototype strain) with alanine (A2378) before IFN treatment was frequent in both SVR and ETR after IFN treatment, whereas that with threonine (T2378) was significant in NR. Moreover, substitution of threonine for alanine in HCV subgenomic replicon showed a 3- to 4-fold reduction of IFN transactivation and replication even in the presence of IFN, suggesting an IFN-resistant phenotype. These observations suggest that a single amino acid in position 2378 of NS5A plays important roles for both ALT normalization and IFN response in HCV-1b infected patients.
干扰素(IFN)治疗丙型肝炎的疗效与丙型肝炎病毒(HCV)非结构蛋白 5A(NS5A)中干扰素敏感性决定区或 V3 结构域的突变密切相关。然而,丙氨酸氨基转移酶(ALT)正常化与 NS5A 变异性之间的关系尚不清楚。为了阐明 NS5A 的这些特征,我们检测了 33 例 HCV 基因型 1b 感染患者的 NS5A 遗传变异性:11 例持续病毒学应答(SVR),11 例治疗结束时 ALT 正常(<40IU/L)的应答(ETR),11 例 IFN 治疗>24 周后 ALT 异常(>40IU/L)的无应答(NR)。IFN 治疗前位置 2378 处的丙氨酸(A2378)(继 HCV-J 原型株之后)在 IFN 治疗后的 SVR 和 ETR 中均很常见,而在 NR 中则为苏氨酸(T2378)。此外,在 HCV 亚基因组复制子中,苏氨酸取代丙氨酸即使在 IFN 存在的情况下也会导致 IFN 转激活和复制减少 3-4 倍,表明存在 IFN 耐药表型。这些观察结果表明,NS5A 位置 2378 处的单个氨基酸在 HCV-1b 感染患者的 ALT 正常化和 IFN 反应中均起着重要作用。